

Erratum

Breast Care 2017;12:60
DOI: 10.1159/000464124

In the article Breast Care 2016;11:424–426 (DOI:10.1159/000453572),

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature

The correct list of authors and affiliations should be as follows:

Gevorgyan A.^a · Bregni G.^b · Paolini B.^c · Galli G.^a · Zanardi E.^b · de Braud F.^a · Di Cosimo S.^a

^aDepartment of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy;

^bMedical Oncology Unit 1, IRCCS AOU San Martino-IST, Genoa, Italy;

^cDepartment of Pathology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy

The correct legend for fig. 1 should be as follows:

Fig. 1. a Hematoxylin and eosin-stained (H&E) section of primary breast cancer, 1984 (1, 2) signed out as ‘malignant carcinoid’. Note the presence of an in situ component with same cytological details and positivity of Grimelius silver stain (3). Morphology of relapse occurring in 1987 (4) is strictly similar, with more pronounced pseudorosettes formation. **b** H&E section of bone metastasis (1). Cancer nests showed immunohistochemical positivity for estrogen receptors (2), very low proliferative rate with Ki 67 (< 5%, 3) and 2+ score of HER2/neu (ASCO/ CAP guidelines 2013, 4). **c** Biopsy of pelvic mass shows invasive carcinoma with neuroendocrine morphology (1), with intense positivity to synaptophysin (2) and chromogranin-A (2). HER2/neu was confirmed as 2+ score (4). Note that granular positivity of chromogranin-A (3) is very similar in distribution to the Grimelius positivity observed in 1984.